BREWER RICHARD B Form 3 February 05, 2009 FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB approval

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person <u>*</u> BREWER RICHARD B			2. Date of Event Requiring Statement (Month/Day/Year)	 3. Issuer Name and Ticker or Trading Symbol ARCA biopharma, Inc. [ABIO] 				
(Last)	(First)	(Middle)	01/27/2009	4. Relationship of Reporting Person(s) to Issuer			5. If Amendment, Date Original Filed(Month/Day/Year)	
C/O ARCA INC., 800 SUITE 200 BROOMFIE	(Street)	PLACE,		(Check all applicable) <u>X</u> Director <u>10%</u> Owner <u>X</u> Officer <u>Other</u> (give title below) (specify below) President and CEO		 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person 		
(City)	(State)	(Zip)	Table I - I	Table I - Non-Derivative Securities Beneficially Owned				
1.Title of Secu (Instr. 4)	rity		2. Amount o Beneficially (Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)		ture of Indirect Beneficial ership : 5)	
Common Ste	ock		83,490		D	Â		
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)								
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.								

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security	2. Date Exercisable and	3. Title and Amount of	4.	5.	6. Nature of Indirect
(Instr. 4)	Expiration Date	Securities Underlying	Conversion	Ownership	Beneficial Ownership
	(Month/Day/Year)	Derivative Security	or Exercise	Form of	(Instr. 5)
		(Instr. 4)	Price of	Derivative	
			Derivative	Security:	

3235-0104

January 31,

2005

0.5

Number:

Expires:

response...

Estimated average burden hours per

Edgar Filing: BREWER RICHARD B - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Option to Purchase Common Stock	(1)	11/02/2016	Common Stock	165,644	\$ 0.9	D	Â
Option to Purchase Common Stock	(2)	01/22/2019	Common Stock	25,047	\$ 5.57	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
BREWER RICHARD B C/O ARCA BIOPHARMA, INC. 8001 ARISTA PLACE, SUITE 200 BROOMFIELD, CO 80021	X	Â	President and CEO	Â		
Signatures						
Patrick Wheeler, attorney in fact	02/05/2009					
<u>**</u> Signature of Reporting Person	Date					

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The options are exercisable immediately and if exercised are subject to ARCA's right of repurchase, which lapses at the rate of 25% upon (1) grant and 6.25% at the end of each three-month period following the first anniversary of the November 2, 2006 grant date. Of these
- options, as of January 27, 2009, 82,822 were subject to a right of repurchase in favor of ARCA.
- (2) The options vest in equal monthly installments over a four year period from the date of grant

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.